Astrazeneca (AZN) Change in Acquisitions & Divestments (2009 - 2026)

Astrazeneca's Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $40.0 million for Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments fell 64.91% year-over-year to $40.0 million; the TTM figure through Jun 2026 stood at -$29.0 million (down 128.16% YoY), while the FY2025 annual figure was $131.0 million, up 336.67% from the prior year.
• Change in Acquisitions & Divestments for Q2 2026 stood at $40.0 million, up from -$85.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $114.0 million in Q2 2025, with the low at -$85.0 million in Q1 2026.
• The 5-year median for Change in Acquisitions & Divestments is $9.0 million (2023), against an average of $15.4 million.
• The sharpest annual moves came in 2023 and 2026: Change in Acquisitions & Divestments soared 775.0% in 2023, then tumbled 8600.0% in 2026.
• Astrazeneca's Change in Acquisitions & Divestments stood at -$12.0 million in 2022, then jumped by 775.0% to $81.0 million in 2023, then plunged by 145.68% to -$37.0 million in 2024, then jumped by 124.32% to $9.0 million in 2025, then surged by 344.44% to $40.0 million in 2026.
• Business Quant data shows AZN's Change in Acquisitions & Divestments at $40.0 million in Q2 2026, -$85.0 million in Q1 2026, and $9.0 million in Q4 2025.